Page 19 - Hal Barron News Today

GSKs Jemperli approved by US regulator for endometrial cancer Thu, 22nd Apr 2021 21:06 (Alliance News) - GlaxoSmithKline PLC said Thursday the US Food & Drug Administration has approved Jemperli for for women with recurrent or advanced dMMR endometrial cancer. Dostarlimab, the medical name for Jemperli, is indicated for the treatment of adult patients with mismatch repair deficient, dMMR, recurrent or advanced endometrial cancer, as determined by an FDA approved test, that have progressed on o...

Subscription Notification We have noticed that there is an issue with your subscription billing details. Please update your billing details here Please update your billing information The subscription details associated with this account need to be updated. Please update your billing details here to continue enjoying your subscription. Your subscription will end shortly Please update your billing details here to continue enjoying your access to the most informative and considered journalism in ...

The arrival of activist investor Elliott Management on the doorstep of Glaxosmithklines glistening headquarters in Brentford has caught Emma Walmsley and her team on the hop.  The pharmaceutical group is aware of investor disquiet about a lagging share price compared with peers on both sides of the Atlantic.  The crossover in valuations between its main UK counterpart Astrazeneca and GSK, previously regarded as the UKs top rated big pharma group, has underlined perceived under-performance. Un...

Dive Brief: GlaxoSmithKline will stop enrolling cancer patients into two mid-stage studies testing a closely watched cancer immunotherapy alongside Merck & Co.s Keytruda, marking another setback for the British drugmakers ambitions in oncology research. The decision followed a recommendation from an independent monitoring committee that oversees one of the trials. In a Wednesday statement, GSK said it will evaluate the "totality of the data" to determine the impact on its broader development pl...

The worlds largest vaccine business has been on the sidelines of the pandemic response. GSK is facing an exodus of US vaccine scientists, with several dozen leaving in the past year. Former GSK employees expressed frustration with the companys bureaucracy and pandemic response. On a mild day in December 2016, GlaxoSmithKline executives snipped an orange ribbon, ushering in what they hoped would be a new chapter for the pharmaceutical giant. GSK had just helped the world respond to the viral sca...

Subscribe Monoclonal antibodies: GSK and Vir to seek US approval for their COVID-19 candidate, EMA starts rolling review of Lillys medicines By Jane Byrne GSK and its partner, Vir Biotechnology, report that their jointly developed monoclonal antibody, VIR-7831, reduces hospitalization and risk of death in early treatment of adults with COVID-19. A global phase 3 clinical trial, COMET-ICE, based its initial analysis on data ...

Advances in medicine to treat COVID and immunize the population have been astounding; more important developments this week

Based on the profound results, the British pharmaceuticals company, led by chief exec Emma Walmsley (pictured), said it was urgently seeking approval from regulators for the antibody treatment.

A monoclonal antibody drug reduces hospital admission or death from Covid-19 by 85, the pharmaceutical giant GlaxoSmithKline (GSK) has announced.

Monoclonal antibodies are laboratory-produced molecules that mimic human antibodies.